Looking at the universe of stocks we cover at Dividend Channel, on 1/16/14, Main Street Capital Corporation (MAIN - Get Report) will trade ex-dividend, for its monthly dividend of $0.165, payable on 2/14/14. As a percentage of MAIN's recent stock price of $33.93, this dividend works out to approximately 0.49%.Below is a dividend history chart for MAIN, showing historical dividends prior to the most recent $0.165 declared by Main Street Capital Corporation: In general, dividends are not always predictable; but looking at the history above can help in judging whether the most recent dividend from MAIN is likely to continue, and whether the current estimated yield of 5.84% on annualized basis is a reasonable expectation of annual yield going forward.The chart below shows the one year performance of MAIN shares, versus its 200 day moving average: Looking at the chart above, MAIN's low point in its 52 week range is $25.52 per share, with $34.75 as the 52 week high point — that compares with a last trade of $33.95. According to the ETF Finder at ETF Channel, MAIN makes up 5.23% of the BDC Income ETF ( BIZD) which is trading relatively unchanged on the day Tuesday. In Tuesday trading, Main Street Capital Corporation shares are currently up about 0.3% on the day.
More from Stocks
The Charts of Zendesk Could Use Some Meditation and Stress Management
Where are we headed next?
The Impressive Rally in HubSpot Is Likely to Continue to the $250 Area
Let's check out the charts.
Dow Rises After Yield Curve Returns to Normal Though Recession Fears Remain
Stocks are mixed as bond yields invert - a possible recession warning - and then normalize ahead of Fed Chairman Jerome Powell's scheduled address Friday at the annual Jackson Hole Economic Symposium.
GameStop Spikes After Investor Michael Burry Goes Long on Video Game Retailer
Michael Burry is famous for being one of the first investors to short subprime mortgages before the financial crisis, and was depicted by Christian Bale in the movie "The Big Short."
Retrophin Tanks After Neurological Treatment Fails Late-Stage Study
The treatment, fosmetpantotenate, fails to meet its primary endpoint when compared to a control group being treated with a placebo, the company says.